Abstract | BACKGROUND/AIM: We have previously reported the identification of the cytotoxic chemotype compound-I (CC-I) from a chemical library screening against glioblastoma. MATERIALS AND METHODS: The biological activity of CC-I on drug-resistant neuroblastomas [e.g., HFE gene variant C282Y stably transfected human neuroblastoma SH-SY5Y cells (C282Y HFE/SH-SY5Y), SK-N-AS] was characterized using cell culture models and in vivo mouse tumor models. RESULTS: CONCLUSION: CC-I may be an effective therapeutic option for therapy-resistant neuroblastomas, especially if they express the C282Y HFE gene variant. Its anti- tumor effects are possibly through HSP27-Akt-JNK activation.
|
Authors | Sang Y Lee, Becky Slagle-Webb, Arun K Sharma, James R Connor |
Journal | Anticancer research
(Anticancer Res)
Vol. 41
Issue 3
Pg. 1171-1181
(Mar 2021)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 33788708
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Antineoplastic Agents
- HSP27 Heat-Shock Proteins
- Thiobarbiturates
- Proto-Oncogene Proteins c-akt
- JNK Mitogen-Activated Protein Kinases
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Cell Line, Tumor
- Child
- Child, Preschool
- Female
- Fibroblasts
(drug effects)
- HSP27 Heat-Shock Proteins
(physiology)
- Humans
- JNK Mitogen-Activated Protein Kinases
(physiology)
- Male
- Mice
- Neuroblastoma
(drug therapy, pathology)
- Phosphorylation
- Proto-Oncogene Proteins c-akt
(physiology)
- Thiobarbiturates
(pharmacology, therapeutic use)
|